1. 71% patients achieved complete remission or complete remission with incomplete recovery following KTE-X19 infusion. 2. The majority of adverse ...
1. In two phase 1 studies, allogenic anti-CD19 CAR T cell (UCART19) treatment showed a manageable safety profile with relapsed ...
1. Patients with a higher disease burden of acute lymphoblastic leukemia (ALL) treated with CD19-specific chimeric antigen receptor (CAR) T ...
1. Compared to standard chemotherapy alone, the addition of the rituximab significantly improves event-free survival among adults with CD20-positive, Philadelphia ...
1. Inotuzumab ozogamaxin (IO) demonstrated significantly higher complete remission rates and median progression-free survival compared to standard chemotherapy in relapsed ...
1. In a retrospective review of over 5000 children with acute lymphoblastic leukemia (ALL) who received asparaginase induction therapy, independent ...
Longitudinal assessment of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy protocol Acute lymphoblastic ...
Originally published by Harvard Health. What Is It? Acute lymphocytic leukemia (ALL) is a type of leukemia. Leukemia is a ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.